Akebia Therapeutics, Inc. AKBA 深 沪
等待开盘 07-01 09:30:00 美东时间
1.14
+0.030
+2.70%
华盛通- 最 高1.29
- 今 开1.285
- 成交量 694.05万股
- 最 低 1.11
- 昨 收 1.11
- 总市值 3.06亿
- 52周最高 4.04
- 市盈率 静 --
- 换手率 2.59%
- 52周最低 0.8227
- 委 比 -14.94%
- 总股本 2.68亿
- 历史最高 31.00
- 量 比 1.40
- 振 幅 16.22%
- 历史最低 0.241
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study After Planned Interim Analysis Based On Recommendation From Independent Data Monitoring Committee, Trial Steering Committee
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, are pleased to announce today the decision by US...
06-30 20:09
Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market
While there are already several drugs already approved to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, Shalabh Gupta isn't fazed. As CEO of Unicycive Therapeutics...
06-22 21:56
Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend Expiration Of Composition Of Matter Patent Covering Vafseo
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and it h...
06-10 20:07
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Akebia Therapeutics announced the granting of a new patent for Vafseo (vadadustat), an oral treatment for anemia in chronic kidney disease patients on dialysis. The patent, listed in the Orange Book, extends the composition of matter patent by 5 years, reinforcing Akebia's intellectual property portfolio, which now includes 14 Orange Book-listed patents expiring through 2036. Vafseo, approved in the U.S. in 2025, remains the only oral HIF-PH inhi...
06-10 12:00
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Akebia Therapeutics, a biopharmaceutical company focused on improving the lives of those affected by kidney disease, granted a newly hired employee options to purchase 8,400 shares of its common stock on May 29, 2026. The options were granted as an inducement for the employee to join the company and align with Nasdaq Listing Rule 5635(c)(4). The exercise price is $1.02 per share, equal to the closing price on the grant date. The options vest o...
06-01 20:05
Akebia Therapeutics Earnings Call: Vafseo Drives Transition
Akebia Therapeutics (($AKBA)) has held its Q1 earnings call. Read on for the ma...
05-20 12:48
Akebia Therapeutics Balances Vafseo Momentum With Headwinds
Akebia Therapeutics (($AKBA)) has held its Q1 earnings call. Read on for the ma...
05-09 09:21
Akebia Therapeutics Announces Publication Of Post-Hoc Win Statistics Analysis Of All-Cause Mortality And Hospitalization From Its Global Phase 3 INNO2VATE Program In The Journal Of The American Society Of Nephrology
"The win statistics analysis highlighted favorable outcomes and potential clinical differentiation for Vafseo that we believe are central to ensure informed clinical decision-making for nephrologists and other care
05-04 20:10
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted stock options to 7 new employees totaling 208,800 shares on April 30, 2026, as an inducement for employment. The options, priced at $1.38 per share (the closing price on the grant date), vest over four years with 25% after the first year and the remaining 75% quarterly thereafter, contingent on continued employment. Each option has a 10-year term and is subject to Akebia’s inducement award program and stock option agre...
05-04 20:05
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics announced the initiation of a Phase 1 clinical trial for AKB-9090, a HIF-PH inhibitor being evaluated for cardiac surgery-associated acute kidney injury (AKI). The randomized, double-blind, placebo-controlled study aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults. AKB-9090 is internally developed and considered a promising candidate for treating AKI, with top-line data expected in e...
04-13 12:00
